1800 Williams St., Suite 200 • Denver, CO 80218
Phone 303-388-4876 • Fax 303-336-2193 • Toll Free 1-800-891-7622

URL http://www.rockymountainbmt.com/news/Acute-lymphoblastic-leukemia-poor-prognosis-predicted-by-Aven-overexpression-4337.html

Acute lymphoblastic leukemia poor prognosis predicted by Aven overexpression

09-15-2006

Poor prognosis in childhood acute lymphoblastic leukemia (ALL) could be linked to Aven overexpression.

"Aven expression has recently been identified as an anti-apoptotic protein. In this study, Aven expression in 91 children with ALL was investigated for possible correlation with clinical features at diagnosis and treatment outcome," researchers in South Korea reported.

"Aven expression was found to be higher in patients {{>=}}10 years old or <1 year (p=.003), and in patients with unfavorable cytogenetic abnormalities (p<.001). Aven expression was also significantly higher in relapsed patients in the standard-risk group. Aven overexpression was an independent poor prognostic factor," explained J. Choi and colleagues, Sungkyunkwan University.

The researchers concluded, "These findings demonstrate that Aven expression can predict prognosis in childhood ALL."

Choi and colleagues published their study in Leukemia Research (Aven overexpression: Association with poor prognosis in childhood acute lymphoblastic leukemia. Leuk Res, 2006;30(8):1019-1025).

For additional information, contact K.W. Sung, Sungkyunkwan University, Samsung Medical Center, Samsung Biomedical Research Institute, Dept. of Pediatrics, 50 Ilwon Dong, Seoul 135710, South Korea.

Publisher contact information for the journal Leukemia Research is: Pergamon-Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England.

Keywords: Seoul, South Korea, Acute Lymphoblastic Leukemia, Apoptosis, Aven, Children, Genetics, Pediatric, Prognosis, Prognostic Factors, Prognostics.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.